查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1403455

到 2030 年抗癲癇藥物市場預測：按癲癇類型、給藥途徑、藥物生成、配銷通路和地區進行的全球市場分析

Antiepileptic Drugs Market Forecasts to 2030 - Global Analysis By Types of Seizures, Route of Administration, Drug Generation, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球抗癲癇藥物市場規模為 185 億美元，預計 2030 年將達到 287 億美元，預測期內複合年成長率為 6.5%。

癲癇是一種神經系統疾病，其特徵是由大腦異常電活動引起的反覆、不可預測的癲癇發作。抗癲癇藥物的作用是調節大腦的電活動，預防或減少導致癲癇發作的異常衝動。 AED 可穩定細胞膜、增強 GABA 等抑制性神經傳導物質、阻斷鈉通道、降低麩胺酸興奮性或調節鈣離子通道。

根據世界衛生組織（WHO）2023年2月9日公佈，全球每年有500萬人被診斷出患有癲癇症。據估計，高所得國家每 10 萬人中就有 49 人患有癲癇。

藥物開發的進展

持續的研究和開發工作正在發現新的劑型、新的作用機制和改進的藥物傳輸系統，這些正在改變抗癲癇治療的模式。引入下一代抗癲癇藥物旨在解決傳統治療方法的局限性，例如副作用和癲癇控制不完全。此外，包括緩釋製劑在內的緩釋性製劑正在改善給藥方案並提高患者的醫囑遵從性和整體治療效果。藥物開發的這些進步正在推動市場需求。

副作用

常見的副作用包括頭暈、疲勞、認知障礙和情緒變化，這些都會顯著影響患者的生活品質。面臨的挑戰是平衡癲癇控制的治療益處與這些副作用的耐受性。此外，副作用的發生可能導致患者不滿意、違規和停止治療，從而抑制抗癲癇治療的有效性。這些副作用是主要的抑制因素和阻礙市場擴張。

癲癇盛行率上升

癲癇是一種以反覆發作為特徵的神經系統疾病，影響著全世界大量患者。癲癇盛行率的上升是由多種因素造成的。首先，診斷技術的改進和對癲癇意識的提高有助於提高檢出率。醫學知識和技術的進步使醫療保健專業人員能夠準確診斷和分類癲癇。宣傳宣傳活動和教育計劃也傳播了有關癲癇症狀和早期診斷重要性的知識，增加了尋求醫療護理的人數。

社會恥辱

儘管對神經系統疾病癲癇的認知取得了進展，但社會誤解仍然存在，也是人們不願意接受適當治療的因素。圍繞癲癇的恥辱可能會導致診斷和治療的延誤，有些人因為害怕社會判斷或歧視而避免透露自己的病情或尋求醫療幫助。不願在公共場合談論癲癇可能會加劇資訊，阻止患者接受必要且有效的抗癲癇藥物治療，並妨礙患者教育。這些因素抑制了市場需求。

COVID-19 的影響

COVID-19 大流行嚴重影響了抗癲癇藥物 (AED) 市場。這場大流行凸顯了確保醫療保健系統具有彈性的重要性。遠端醫療解決方案和遠端患者監護已成為人們關注的焦點，為癲癇管理提供了另一種方法。此外，我們對解決 COVID-19 神經系統併發症的研究和開發的關注間接有助於更好地了解癲癇及相關疾病。此外，供應鏈中斷和經濟不確定性正在影響 AED 的生產和分銷，進而影響市場動態。

預計第三代細分市場在預測期內將是最大的

第三代細分市場預計將佔據最大佔有率。這些藥物，包括拉科醯胺、艾斯利卡西平和吡崙帕奈，在治療癲癇發作方面顯示出更高的特異性和有效性。第三代 AED 通常針對新的分子途徑，從而產生頻譜作用和調節神經元活動的高選擇性。第三代 AED 的主要特點之一是注重最大限度地減少副作用和藥物交互作用，從而提高整體耐受性。這對於提高患者對治療方法的醫囑遵從性尤其重要。

預計口腔細分市場在預測期內複合年成長率最高

預計口服藥物領域在預測期內將出現良好的成長。口服給藥時，抗癲癇藥物以錠劑、膠囊或液體的形式服用，使得藥物從胃腸道吸收方便、有效率。口服給藥為藥物製劑提供了彈性，並允許開發隨時間逐漸釋放藥物的緩釋緩釋性。此功能可保持血液中的藥物濃度恆定，最佳化治療效果並最大限度地減少可能引發癲癇發作的波動。

佔比最高的地區

由於強大的醫療基礎設施、先進的醫學研究和癲癇相關疾病的高盛行率，北美在預測期內佔據了最大的市場佔有率。該地區的製藥業十分完善，在研發方面的大量投資推動了抗癲癇治療的創新。此外，主要市場參與者的存在和最尖端科技的採用有助於該地區在推進治療方案方面處於領先地位。

複合年成長率最高的地區：

由於認知的提高、醫療基礎設施的改善以及癲癇相關疾病盛行率的上升，預計亞太地區在預測期內將實現盈利成長。向更好的診斷和加強患者教育的轉變進一步推動了該地區抗癲癇藥物的需求。此外，該地區多樣化的人口結構和強大的患者基礎為參與抗癲癇藥物開發和銷售的製藥公司提供了巨大的成長機會。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球抗癲癇藥物市場：依癲癇類型

  • 局部性發作
  • 整體癲癇發作
  • 其他類型的癲癇發作

第6章全球抗癲癇藥物市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 其他給藥途徑

第7章 全球抗癲癇藥物市場：新藥生成

  • 第一代
    • Carbamazepine
    • 苯妥英
    • 丙戊酸
    • 奧卡西平
    • 乙舒醯亞胺
    • 托吡酯
    • 撲米酮
    • 苯巴比妥
  • 第二代
    • 普瑞巴林
    • 拉莫三嗪
    • 左乙拉西坦
    • 盧非醯胺
    • 醋酸艾斯利卡西平
    • 拉科醯胺
    • 吡崙帕奈
    • 唑尼沙胺
  • 第三代

第8章全球抗癲癇藥物市場：依配銷通路

  • 零售藥房
  • 醫院藥房
  • 網路藥房
  • 其他配銷通路

第9章全球抗癲癇藥物市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第10章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司簡介

  • Eisai Co., Ltd.
  • Novartis AG
  • Merck KGaA
  • Teva Pharmaceutical Industries Ltd.
  • AstraZeneca
  • Abbott
  • Sanofi
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Dr. Reddy's Laboratories Ltd.
  • Johnson & Johnson Service, Inc.
  • Zogenix
  • Alkem Labs
  • SK Biopharmaceuticals
  • Sun Pharmaceutical Industries Ltd.
Product Code: SMRC24680

According to Stratistics MRC, the Global Antiepileptic Drugs Market is accounted for $18.5 billion in 2023 and is expected to reach $28.7 billion by 2030 growing at a CAGR of 6.5% during the forecast period. Epilepsy is a neurological disorder characterized by recurrent and unpredictable seizures, which are caused by abnormal electrical activity in the brain. Antiepileptic drugs work by modulating the electrical activity in the brain, preventing or reducing abnormal impulses that lead to seizures. AEDs stabilize cell membranes, enhance inhibitory neurotransmitters like GABA, block sodium channels, reduce glutamate excitability, or modulate calcium channels.

According to World Health Organization (WHO) on February 09, 2023, 5 million people are diagnosed globally with epilepsy every year. Epilepsy is estimated to affect 49 persons out of every 100,000 in high-income countries every year.

Market Dynamics:

Driver:

Advancements in drug development

Continuous research and development efforts have led to the discovery of new formulations, novel mechanisms of action, and improved drug delivery systems, revolutionizing the landscape of antiepileptic treatments. The introduction of next-generation antiepileptic drugs has aimed to address limitations associated with traditional therapies, such as adverse side effects and incomplete seizure control. Additionally, advanced formulations, including extended-release versions, offer improved dosing regimens, enhancing patient adherence and overall treatment efficacy. These advancements in drug development propel market demand.

Restraint:

Side effects

Common side effects include dizziness, fatigue, cognitive impairment, and mood alterations, which can significantly impact patients' quality of life. The challenge lies in balancing the therapeutic benefits of seizure control with the tolerability of these side effects. Moreover, the occurrence of adverse reactions may lead to patient dissatisfaction, non-compliance, or discontinuation of treatment, impeding the effectiveness of antiepileptic therapy. These side effects pose a significant restraint, hampering market expansion.

Opportunity:

Rising prevalence of epilepsy

Epilepsy is a neurological disorder characterized by recurrent seizures, and it affects a substantial number of individuals worldwide. The rising prevalence of epilepsy can be attributed to several factors. Firstly, improved diagnostic techniques and increased awareness of epilepsy have contributed to a higher detection rate. As medical knowledge and technological advancements have improved, healthcare professionals are better equipped to diagnose and classify epilepsy accurately. Additionally, awareness campaigns and educational programs have helped spread knowledge about epilepsy symptoms and the importance of early diagnosis, leading to more individuals seeking medical attention.

Threat:

Social stigma

Despite advancements in understanding the neurological condition, societal misconceptions persist, contributing to reluctance among individuals to seek appropriate treatment. The stigma surrounding epilepsy may lead to under diagnosis and under treatment, as some individuals may avoid disclosing their condition or seeking medical help due to fear of social judgment or discrimination. This unwillingness to discuss epilepsy in public can worsen misinformation, prevent patients from receiving the necessary and efficient treatment that antiepileptic medications provide, and impede patient education. These factors impede market demand.

COVID-19 Impact

The COVID-19 pandemic has significantly impacted the Antiepileptic Drugs (AEDs) market. Pandemic has underscored the importance of ensuring a resilient healthcare system. Telehealth solutions and remote patient monitoring have gained prominence, providing alternative avenues for epilepsy management. Additionally, the focus on research and development to address neurological complications of COVID-19 has indirectly contributed to advancements in understanding epilepsy and related disorders. Moreover, supply chain disruptions and economic uncertainties have impacted the production and distribution of AEDs, affecting market dynamics.

The third generation segment is expected to be the largest during the forecast period

The third generation segment is estimated to hold the largest share. These drugs, such as lacosamide, eslicarbazepine, and perampanel, exhibit enhanced specificity and efficacy in managing epileptic seizures. Third-generation AEDs often target novel molecular pathways, providing a broader spectrum of action and greater selectivity in modulating neuronal activity. One key feature of third-generation AEDs is their focus on minimizing side effects and drug interactions, thus improving overall tolerability. This is particularly important in enhancing patient adherence to treatment regimens.

The Oral segment is expected to have the highest CAGR during the forecast period

The Oral segment is anticipated to have lucrative growth during the forecast period. Oral administration involves the ingestion of antiepileptic drugs in the form of tablets, capsules, or liquids, allowing for convenient and efficient drug absorption through the gastrointestinal tract. The oral route provides flexibility in drug formulation, enabling the development of extended-release formulations that release the medication gradually over time. This feature helps maintain consistent drug levels in the bloodstream, optimizing therapeutic efficacy and minimizing fluctuations that could trigger seizures.

Region with largest share:

North America commanded the largest market share during the extrapolated period owing to robust healthcare infrastructure, advanced medical research, and a high prevalence of epilepsy-related disorders. The region's well-established pharmaceutical industry, coupled with substantial investments in research and development, fosters innovation in antiepileptic treatments. Moreover, the presence of key market players and the adoption of cutting-edge technologies contribute to the region's leadership in advancing treatment options.

Region with highest CAGR:

Asia Pacific is expected to witness profitable growth over the projection period, due to increasing awareness, growing healthcare infrastructure, and a rising incidence of epilepsy-related disorders. A shift towards better diagnostics and increased patient education further fuels the demand for antiepileptic medications in this region. Additionally, with a diverse demographic and a substantial patient base, the region represents a significant growth opportunity for pharmaceutical companies engaged in the development and distribution of antiepileptic drugs.

Key players in the market:

Some of the key players in the Antiepileptic Drugs Market include Eisai Co., Ltd., Novartis AG, Merck KGaA, Teva Pharmaceutical Industries Ltd., AstraZeneca, Abbott, Sanofi, Pfizer Inc., GlaxoSmithKline plc, Dr. Reddy's Laboratories Ltd., Johnson & Johnson Service, Inc., Zogenix, Alkem Labs, SK Biopharmaceuticals and Sun Pharmaceutical Industries Ltd.

Key Developments:

In June 2023, Pfizer announced a strategic collaboration with Truveta to deliver new safety insights on a continuous basis, using verifiable real-world data at scale.

In January 2021, Novartis announced collaboration with Alnylam to leverage Alnylam's proven, proprietary siRNA technology to inhibit a target discovered at the Novartis Institutes for BioMedical Research, potentially leading to development of a treatment designed to promote the regrowth of functional liver cells and to provide an alternative to transplantation for patients with liver failure.

Types of Seizures Covered:

  • Partial-onset seizures
  • Generalized seizures
  • Other Types of Seizures

Route of Administrations Covered:

  • Intravenous
  • Oral
  • Other Route of Administrations

Drug Generations Covered:

  • First Generation
  • Second Generation
  • Third Generation

Distribution Channels Covered:

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
  • Other Distribution Channels

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Antiepileptic Drugs Market, By Types of Seizures

  • 5.1 Introduction
  • 5.2 Partial-onset seizures
  • 5.3 Generalized seizures
  • 5.4 Other Types of Seizures

6 Global Antiepileptic Drugs Market, By Route of Administration

  • 6.1 Introduction
  • 6.2 Intravenous
  • 6.3 Oral
  • 6.4 Other Route of Administrations

7 Global Antiepileptic Drugs Market, By Drug Generation

  • 7.1 Introduction
  • 7.2 First Generation
    • 7.2.1 Carbamazepine
    • 7.2.2 Phenytoin
    • 7.2.3 Valproate
    • 7.2.4 Oxycarbazepine
    • 7.2.5 Ethosuximide
    • 7.2.6 Topiramate
    • 7.2.7 Primidone
    • 7.2.8 Phenobarbital
  • 7.3 Second Generation
    • 7.3.1 Pregabalin
    • 7.3.2 Lamotrigine
    • 7.3.3 Levetiracetam
    • 7.3.4 Rufinamide
    • 7.3.5 Eslicarbazepine acetate
    • 7.3.6 Lacosamide
    • 7.3.7 Perampanel
    • 7.3.8 Zonisamide
  • 7.4 Third Generation

8 Global Antiepileptic Drugs Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Retail Pharmacies
  • 8.3 Hospital Pharmacies
  • 8.4 Online Pharmacies
  • 8.5 Other Distribution Channels

9 Global Antiepileptic Drugs Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Eisai Co., Ltd.
  • 11.2 Novartis AG
  • 11.3 Merck KGaA
  • 11.4 Teva Pharmaceutical Industries Ltd.
  • 11.5 AstraZeneca
  • 11.6 Abbott
  • 11.7 Sanofi
  • 11.8 Pfizer Inc.
  • 11.9 GlaxoSmithKline plc
  • 11.10 Dr. Reddy's Laboratories Ltd.
  • 11.11 Johnson & Johnson Service, Inc.
  • 11.12 Zogenix
  • 11.13 Alkem Labs
  • 11.14 SK Biopharmaceuticals
  • 11.15 Sun Pharmaceutical Industries Ltd.

List of Tables

  • Table 1 Global Antiepileptic Drugs Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Antiepileptic Drugs Market Outlook, By Types of Seizures (2021-2030) ($MN)
  • Table 3 Global Antiepileptic Drugs Market Outlook, By Partial-onset seizures (2021-2030) ($MN)
  • Table 4 Global Antiepileptic Drugs Market Outlook, By Generalized seizures (2021-2030) ($MN)
  • Table 5 Global Antiepileptic Drugs Market Outlook, By Other Types of Seizures (2021-2030) ($MN)
  • Table 6 Global Antiepileptic Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 7 Global Antiepileptic Drugs Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 8 Global Antiepileptic Drugs Market Outlook, By Oral (2021-2030) ($MN)
  • Table 9 Global Antiepileptic Drugs Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
  • Table 10 Global Antiepileptic Drugs Market Outlook, By Drug Generation (2021-2030) ($MN)
  • Table 11 Global Antiepileptic Drugs Market Outlook, By First Generation (2021-2030) ($MN)
  • Table 12 Global Antiepileptic Drugs Market Outlook, By Carbamazepine (2021-2030) ($MN)
  • Table 13 Global Antiepileptic Drugs Market Outlook, By Phenytoin (2021-2030) ($MN)
  • Table 14 Global Antiepileptic Drugs Market Outlook, By Valproate (2021-2030) ($MN)
  • Table 15 Global Antiepileptic Drugs Market Outlook, By Oxycarbazepine (2021-2030) ($MN)
  • Table 16 Global Antiepileptic Drugs Market Outlook, By Ethosuximide (2021-2030) ($MN)
  • Table 17 Global Antiepileptic Drugs Market Outlook, By Topiramate (2021-2030) ($MN)
  • Table 18 Global Antiepileptic Drugs Market Outlook, By Primidone (2021-2030) ($MN)
  • Table 19 Global Antiepileptic Drugs Market Outlook, By Phenobarbital (2021-2030) ($MN)
  • Table 20 Global Antiepileptic Drugs Market Outlook, By Second Generation (2021-2030) ($MN)
  • Table 21 Global Antiepileptic Drugs Market Outlook, By Pregabalin (2021-2030) ($MN)
  • Table 22 Global Antiepileptic Drugs Market Outlook, By Lamotrigine (2021-2030) ($MN)
  • Table 23 Global Antiepileptic Drugs Market Outlook, By Levetiracetam (2021-2030) ($MN)
  • Table 24 Global Antiepileptic Drugs Market Outlook, By Rufinamide (2021-2030) ($MN)
  • Table 25 Global Antiepileptic Drugs Market Outlook, By Eslicarbazepine acetate (2021-2030) ($MN)
  • Table 26 Global Antiepileptic Drugs Market Outlook, By Lacosamide (2021-2030) ($MN)
  • Table 27 Global Antiepileptic Drugs Market Outlook, By Perampanel (2021-2030) ($MN)
  • Table 28 Global Antiepileptic Drugs Market Outlook, By Zonisamide (2021-2030) ($MN)
  • Table 29 Global Antiepileptic Drugs Market Outlook, By Third Generation (2021-2030) ($MN)
  • Table 30 Global Antiepileptic Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 31 Global Antiepileptic Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 32 Global Antiepileptic Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 33 Global Antiepileptic Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 34 Global Antiepileptic Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.